William Blair
William Blair Initiates Coverage of Bio-Techne With Outperform Rating
The investment bank emphasized Bio-Techne's position in multiple high-growth and attractive end markets, including cell and gene therapy, spatial biology, and liquid biopsy.
William Blair Initiates Coverage of MDxHealth With Outperform Rating
A letter to investors noted the company's dedicated focus on prostate cancer diagnostics, which de-risks the firm's growth outlook and path to profitability.
William Blair Downgrades Lucira Health to Market Perform
As a result of the downgrade, the bank also significantly reduced revenue and volume estimates for 2021 and 2022.
William Blair Initiates Coverage of 10x Genomics With Outperform Rating
Analysts for the investment bank, which co-managed a recent 10x stock offering, said the company could "redefine the way biological analysis is performed."
Roche to Acquire GenMark Diagnostics for $1.8B
Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share.